Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group.

Humans Carcinoma, Renal Cell / pathology Prognosis Kidney Neoplasms / pathology Retrospective Studies Japan Nephrectomy
Localized and locally advanced renal cell carcinoma Nephrectomy Overall survival Prognostic model Recurrence-free survival Renal cell carcinoma

Journal

International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 06 06 2023
accepted: 06 08 2023
medline: 1 11 2023
pubmed: 23 9 2023
entrez: 22 9 2023
Statut: ppublish

Résumé

The Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC). A database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018. Using univariable and multivariable analyses, we retrospectively analyzed disease-free survival (DFS) and overall survival (OS) in this database, constructed a new prognostic model according to these results, and estimated the model fit using c-index on the new and mIMDC models. Independent poorer prognostic factors for both DFS and OS include the following: ≥ 1 Eastern Cooperative Oncology Group performance status, 2.0 mg/dL C-reactive protein, and > upper normal limit of white blood cell count. The median DFS in the favorable (no factor), intermediate (one factor), and poor-risk group (two or three factors) was 76.1, 14.3, and 4.0 months, respectively (P < 0.001). The 3-year OS in the favorable, intermediate, and poor-risk group were 92%, 44%, and 0%, respectively (P < 0.001). The c-indices of the new and mIMDC models were 0.67 and 0.60 for DFS (P = 0.060) and 0.74 and 0.63 for OS (P = 0.012), respectively. The new preoperative prognostic model in LLRCC can be used in patient care and clinical trials.

Sections du résumé

BACKGROUND BACKGROUND
The Modified International Metastatic Renal Cell Carcinoma Dataset Consortium model (mIMDC) is a preoperative prognostic model for pT3cN0M0 renal cell carcinoma (RCC). This study aimed to validate the mIMDC and to construct a new model in a localized and locally advanced RCC (LLRCC).
METHODS METHODS
A database was established (the Michinoku Japan Urological Cancer Study Group database) consisting of 79 patients who were clinically diagnosed with LLRCC (cT3b/c/4NanyM0) and underwent radical nephrectomy from December 2007 to May 2018. Using univariable and multivariable analyses, we retrospectively analyzed disease-free survival (DFS) and overall survival (OS) in this database, constructed a new prognostic model according to these results, and estimated the model fit using c-index on the new and mIMDC models.
RESULTS RESULTS
Independent poorer prognostic factors for both DFS and OS include the following: ≥ 1 Eastern Cooperative Oncology Group performance status, 2.0 mg/dL C-reactive protein, and > upper normal limit of white blood cell count. The median DFS in the favorable (no factor), intermediate (one factor), and poor-risk group (two or three factors) was 76.1, 14.3, and 4.0 months, respectively (P < 0.001). The 3-year OS in the favorable, intermediate, and poor-risk group were 92%, 44%, and 0%, respectively (P < 0.001). The c-indices of the new and mIMDC models were 0.67 and 0.60 for DFS (P = 0.060) and 0.74 and 0.63 for OS (P = 0.012), respectively.
CONCLUSION CONCLUSIONS
The new preoperative prognostic model in LLRCC can be used in patient care and clinical trials.

Identifiants

DOI: 10.1007/s10147-023-02401-2 PMID: 37740070
pubmed: 37740070
doi: 10.1007/s10147-023-02401-2
pii: 10.1007/s10147-023-02401-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1538-1544

Informations de copyright

© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Références

Dabestani S, Thorstenson A, Lindblad P et al (2016) Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol 34(8):1081–1086. https://doi.org/10.1007/s00345-016-1773-y
doi: 10.1007/s00345-016-1773-y pubmed: 26847337
Cosso F, Roviello G, Nesi G et al (2016) Adjuvant therapy for renal cell carcinoma: hype or hope?. Int J Mol Sci. https://doi.org/10.3390/ijms24044243
doi: 10.1007/s00345-016-1773-y
Ravaud A, Motzer RJ, Pandha HS et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. https://doi.org/10.1056/NEJMoa1611406
doi: 10.1056/NEJMoa1611406 pubmed: 27718781
Motzer RJ, Ravaud A, Patard JJ et al (2018) Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol 73(1):62–68. https://doi.org/10.1016/j.eururo.2017.09.008
doi: 10.1016/j.eururo.2017.09.008 pubmed: 28967554
Haas NB, Manola J, Uzzo RG et al (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016. https://doi.org/10.1016/s0140-6736(16)00559-6
doi: 10.1016/s0140-6736(16)00559-6 pubmed: 26969090 pmcid: 4878938
Motzer RJ, Haas NB, Donskov F et al (2017) Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35(35):3916–3923. https://doi.org/10.1200/jco.2017.73.5324
doi: 10.1200/jco.2017.73.5324 pubmed: 28902533 pmcid: 6018511
Powles T, Tomczak P, Park SH et al (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(9):1133–1144. https://doi.org/10.1016/s1470-2045(22)00487-9
doi: 10.1016/s1470-2045(22)00487-9 pubmed: 36055304
Vogl UM, McDermott D, Powles T (2023) Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers. Lancet. https://doi.org/10.1016/s0140-6736(22)02631-9
doi: 10.1016/s0140-6736(22)02631-9 pubmed: 36774931
Pal SK, Uzzo R, Karam JA et al (2022) Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 400(10358):1103–1116. https://doi.org/10.1016/s0140-6736(22)01658-0
doi: 10.1016/s0140-6736(22)01658-0 pubmed: 36099926
Haidar GM, Hicks TD, El-Sayed HF et al (2017) Treatment options and outcomes for caval thrombectomy and resection for renal cell carcinoma. J Vasc Surg Venous Lymphat Disord 5(3):430–436. https://doi.org/10.1016/j.jvsv.2016.12.011
doi: 10.1016/j.jvsv.2016.12.011 pubmed: 28411712
Warren H, Fernando A, Thomas K et al (2019) Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International metastatic renal cell cancer database consortium (IMDC) score. BJU Int 124(3):462–468. https://doi.org/10.1111/bju.14755
doi: 10.1111/bju.14755 pubmed: 30908845
Kattan MW, Reuter V, Motzer RJ et al (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1):63–67
doi: 10.1016/S0022-5347(05)66077-6 pubmed: 11435824
Zisman A, Pantuck AJ, Dorey F et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19(6):1649–1657. https://doi.org/10.1200/jco.2001.19.6.1649
doi: 10.1200/jco.2001.19.6.1649 pubmed: 11250993
Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400. https://doi.org/10.1097/01.ju.0000035885.91935.d5
doi: 10.1097/01.ju.0000035885.91935.d5 pubmed: 12441925
Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671. https://doi.org/10.1002/cncr.11234
doi: 10.1002/cncr.11234 pubmed: 12655523
Karakiewicz PI, Briganti A, Chun FK et al (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25(11):1316–1322. https://doi.org/10.1200/jco.2006.06.1218
doi: 10.1200/jco.2006.06.1218 pubmed: 17416852
Cindolo L, de la Taille A, Messina G et al (2003) A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92(9):901–905. https://doi.org/10.1111/j.1464-410x.2003.04505.x
doi: 10.1111/j.1464-410x.2003.04505.x pubmed: 14632843
Leibovich BC, Lohse CM, Cheville JC et al (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73(5):772–780. https://doi.org/10.1016/j.eururo.2018.01.005
doi: 10.1016/j.eururo.2018.01.005 pubmed: 29398265
Mattila KE, Laajala TD, Tornberg SV et al (2021) A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Sci Rep 11(1):8650. https://doi.org/10.1038/s41598-021-88177-9
doi: 10.1038/s41598-021-88177-9 pubmed: 33883645 pmcid: 8060273
Dolan RD, Laird BJA, Klepstad P et al (2019) An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer. Medicine 98(37):e17019. https://doi.org/10.1097/md.0000000000017019
doi: 10.1097/md.0000000000017019 pubmed: 31517821 pmcid: 6750290
Ruan GT, Xie HL, Zhang HY et al (2022) Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer. Clin Nutr 41(10):2284–2294. https://doi.org/10.1016/j.clnu.2022.08.025
doi: 10.1016/j.clnu.2022.08.025 pubmed: 36096062
Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. https://doi.org/10.1200/JCO.2008.21.4809
doi: 10.1200/JCO.2008.21.4809 pubmed: 19826129
Patel SH, Derweesh IH, Saito K et al (2021) Preoperative elevation of C-reactive protein is a predictor for adverse oncologic survival outcomes for renal cell carcinoma: analysis from the international marker consortium renal cancer (INMARC). Clin Genitourin Cancer 19(4):e206–e215. https://doi.org/10.1016/j.clgc.2021.02.003
doi: 10.1016/j.clgc.2021.02.003 pubmed: 33773937
Hu H, Yao X, Xie X et al (2017) Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol 35(2):261–270. https://doi.org/10.1007/s00345-016-1864-9
doi: 10.1007/s00345-016-1864-9 pubmed: 27255479
Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57(2):317–325. https://doi.org/10.1016/j.eururo.2008.12.026
doi: 10.1016/j.eururo.2008.12.026 pubmed: 19136199
Yasuda Y, Saito K, Yuasa T et al (2013) Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol 18(5):884–889. https://doi.org/10.1007/s10147-012-0454-0
doi: 10.1007/s10147-012-0454-0 pubmed: 22886358
Semeniuk-Wojtas A, Lubas A, Stec R et al (2018) Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive Protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer 16(3):e685–e693. https://doi.org/10.1016/j.clgc.2018.01.010
doi: 10.1016/j.clgc.2018.01.010 pubmed: 29454639
Santoni M, Buti S, Conti A et al (2015) Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol 10(4):517–522. https://doi.org/10.1007/s11523-014-0356-3
doi: 10.1007/s11523-014-0356-3 pubmed: 25559290
Tachibana H, Nemoto Y, Ishihara H et al (2022) Predictive impact of early changes in serum C-Reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer 20(1):e81–e88. https://doi.org/10.1016/j.clgc.2021.10.005
doi: 10.1016/j.clgc.2021.10.005 pubmed: 34772629

Auteurs

Shigemitsu Horie (S)

Department of Urology, Faculty of Medicine, Yamagata University, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan.

Sei Naito (S)

Department of Urology, Faculty of Medicine, Yamagata University, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan. seinaito@med.id.yamagta-u.ac.jp.
ORCID: 0000-0002-6104-4344

Shingo Hatakeyama (S)

Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan.

Shuya Kandori (S)

Department of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Kazuyuki Numakura (K)

Department of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.

Renpei Kato (R)

Department of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan.

Tomoyuki Koguchi (T)

Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Shingo Myoen (S)

Department of Urology, Miyagi Cancer Center, 47-1 Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan.

Yoshihide Kawasaki (Y)

Department of Urology, Tohoku University School of Medicine, 1-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan.

Akihiro Ito (A)

Department of Urology, Tohoku University School of Medicine, 1-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8574, Japan.

Hisanobu Adachi (H)

Department of Urology, Miyagi Cancer Center, 47-1 Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan.

Yoshiyuki Kojima (Y)

Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Wataru Obara (W)

Department of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan.

Tomonori Habuchi (T)

Department of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.

Hiroyuki Nishiyama (H)

Department of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan.

Chikara Ohyama (C)

Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan.

Norihiko Tsuchiya (N)

Department of Urology, Faculty of Medicine, Yamagata University, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Preoperative prognostic model for localized...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › Preoperative prognostic model for localized...
questionsmedicales.fr › Diagnostic › Pronostic › Preoperative prognostic model for localized...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Preoperative prognostic model for localized...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Preoperative prognostic model for localized...
questionsmedicales.fr › Régions géographiques › Iles › Japon › Preoperative prognostic model for localized...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie urogénitale › Procédures de chirurgie urologique › Néphrectomie › Preoperative prognostic model for localized...